GRI (GRI Bio, Inc.) Stock Market Reviews

crown

search

Read and share opinions on GRI (GRI Bio, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

GRI

GRI Bio, Inc.

clarify Biotechnology

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
Sep 11, 2025
GRI Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Sep 3, 2025
GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
Aug 14, 2025
GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment
Jul 31, 2025
GRI Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
Jul 22, 2025
GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
Jul 1, 2025
GRI Bio’s GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
Jun 26, 2025
GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results
May 22, 2025
GRI Bio to Participate in the Virtual Investor Closing Bell Series
May 21, 2025
GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase
May 16, 2025
GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025
May 15, 2025
GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
May 7, 2025

Reviews